Sign Up Now
Get instant access to over 1 million+ study documents
OR
Already registered? click here to login
By creating your account, you agree to our terms of service, privacy policy and student honor code.
The U.S. has supported high prices as the cost for innovation. Since other countries are not playing along, this means that their citizens are benefiting from the innovation paid by Americans.
Conclusion
Big Pharma is at a crossroads today. The previous "great" chronic diseases, like diabetes, heart disease, infectious disease (viral and bacterial) have now been tackled by "blockbuster" drugs.
The high regulatory pressures, price pressures and lack of future such blockbuster markets dictates that pharma companies will have to innovate a lot more in niches -- more products, smaller markets. The large pharma companies which grew up in a time of plenty will therefore have to radically change how they do business, from increasing acquisition (which doesn't always work), cooperative agreements, exemptions from regulatory approval, and other such measures.
At the same time, pharma companies must find a solution to work with fast-growing, important developing markets in such a way that innovation can still be paid for, while the developing...
A good precursor for this is anti-retroviral drugs against AIDS in Southern Africa. Realizing that they could not use patent law to enforce their claims, most big pharma companies came to an understanding with the governments which met everyone's goals.
Bibliography
Bureau, U.S. Census. (2001). An Aging World. Washington, DC: U.S. Census Bureau.
Economist. (2007, October 25). The Pharmaceutical Industry: Beyond the Pill. Economist, p. n.p.
Economist. (2007). World Atlas. London: Economist.
Herper, M. (2007, October 29). Drug Drought. Forbes, p. n.p.
Hoover, D.R. (2002). Medical expenditures during the last year of life: findings from the 1992-1996 Medicare Current Beneficiary Survey - Cost of Care. Health Services Research, n.p.
Pear, R. (2004, January 9). Health Spending Rises to 15% of Economy, a Record Level. New York Times, p. n.p.
Reinhardt, U.E. (2000). Medicare: Its Financing and Future. Health Affairs, n.p.
Pharmaceuticals Industry
Bibliography
Bureau, U.S. Census. (2001). An Aging World. Washington, DC: U.S. Census Bureau.
Economist. (2007, October 25). The Pharmaceutical Industry: Beyond the Pill. Economist, p. n.p.
Economist. (2007). World Atlas. London: Economist.
Herper, M. (2007, October 29). Drug Drought. Forbes, p. n.p.
Sick: The Untold Story of America's Health Care Crisis -- and the People Who Pay the Price. Brief summary of the book, including strengths and weaknesses Jonathan Cohn's "The Untold Story of America's Health-Care Crisis and the People Who Pay the Price" provides a detailed account of challenges that exist within the current healthcare system. The book highlights true stories from five years of travel conducted by the author. During his travels,
Social, Cultural, And Political Influence in Healthcare Delivery Social, cultural, and political inequalities are detrimental to the health and healthcare system of the U.S. This is because the U.S. is one of the most multicultural, overpopulated, diverse and undergoing rapid economic growth. The federal government has embarked on efforts geared at addressing unsustainable costs of health care in the U.S. With the leadership of the current president, Barrack Obama, initiatives of
Pharmaceutical industries have to operate in an environment that is highly competitive and subject to a wide variety of internal and external constraints. In recent times, there has been an increasing trend to reduce the cost of operation while competing with other companies that manufacture products that treat similar afflictions and ailments. The complexities in drug research and development and regulations have created an industry that is subject to intense
Saudi Arabian pharmaceutical market is one of the largest in the Middle East. Within the Gulf Cooperation Council (GCC), Saudi Arabia represents 65%, or $1.7 billion, of the pharmaceutical market (EPSICOM, 2011). This work will analyze the unique opportunities within the Saudi pharmaceutical industry along with challenges, such as heavily regulated price controls and the barriers to access faced by international pharmaceutical companies. Through a better understanding of these
Japanese-American Biopharmaceutical Industry in the 21st Century Optimizing Ethical Drug Availability Between These Two Pharmaceutical Superpowers" The Japanese-American biopharmaceutical industry represents an ongoing international effort between the two top pharmaceutical markets in the world. These two economic powers provide consumers with a majority share of all pharmaceuticals produced in the world. However, a number of pharmaceutical products that are currently available to U.S. residents are unavailable to Japanese consumers. From a humanitarian perspective, this
Management Case Analysis: Pharma, Intellectual Property Prior to 2003, the U.S. pharmaceutical industry heavily restricted intellectual property rights that would allow African countries and others ravaged by AIDS to receive generic medicine There are a great deal of shocking statistics regarding the global populations living with and dying from AIDS, particularly in the age group of 15 -- 19 Health is a factors that is considered relative to a country's wealth; in Africa, a